Evidence map›Paper›PMID 30362250›Full record

ArticleDiabetes, obesity & metabolism2019

Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.

J Hans DeVries, Timothy S Bailey, Anuj Bhargava, Gregg Gerety, Janusz Gumprecht, Simon Heller, Wendy Lane, Carol H Wysham, Bernard Zinman, Britta A Bak and 2 more

2 registry-linked trialsOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02030600 phase3completednot on this map

A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

TypeinterventionalSponsorNovo Nordisk A/SRan2014 to 2015Enrolled721ConditionsDiabetes, Diabetes Mellitus, Type 2Armsinsulin degludec, insulin glargine
NCT02034513 phase3completednot on this map

A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

TypeinterventionalSponsorNovo Nordisk A/SRan2014 to 2016Enrolled501ConditionsDiabetes, Diabetes Mellitus, Type 1Armsinsulin degludec, insulin glargine, insulin aspart
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 7 countries.

J Hans DeVriesUniversity of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-9196-9906
Timothy S BaileyAMCR Institute, Escondido, California.
Anuj BhargavaIowa Diabetes and Endocrinology Research Center, Des Moines, Iowa.
Gregg GeretyAlbany Medical College, Albany, New York.
Janusz GumprechtMedical University of Silesia, Katowice, Poland.
Simon HellerUniversity of Sheffield, Sheffield, UK.ORCID 0000-0002-2425-9565
Wendy LaneMountain Diabetes and Endocrine Center, Asheville, North Carolina.
Carol H WyshamRockwood Clinic, Spokane, Washington.ORCID 0000-0002-3056-0047
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-0041-1876
Britta A BakNovo Nordisk A/S, Søborg, Denmark.
Elise Hachmann-NielsenNovo Nordisk A/S, Søborg, Denmark.
Athena Philis-TsimikasScripps Whittier Diabetes Institute, San Diego, California.
Novo Nordisk (Denmark) · DKAlbany Medical Center Hospital · USAMCR Institute · USIowa Diabetes and Endocrinology Research Center · USMedical University of Silesia · PLMountain Diabetes and Endocrine Center · USMount Sinai Hospital · CAProfil Institute for Metabolic Research · DERockwood Clinic · USScripps Whittier Diabetes Institute · USUniversity of Sheffield · GB

Funding

New York Regional Center for Diabetes Translation Research - Translational Intervention Methodology CoreP30DK111022 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY GONZALEZ · 2016 to 2026
$7.8M
NIDDK NIH HHS P30 DK111022
6 · The paper itself

Abstract

aimsTo investigate the association between day-to-day fasting self-monitored blood glucose (SMBG) variability and risk of hypoglycaemia in type 1 (T1D) and type 2 diabetes (T2D), and to compare day-to-day fasting SMBG variability between treatments with insulin degludec (degludec) and insulin glargine 100 units/mL (glargine U100). MATERIALS AND

methodsData were retrieved from two double-blind, randomized, treat-to-target, two-period (32 weeks each) crossover trials of degludec vs glargine U100 in T1D (SWITCH 1, n = 501) and T2D (SWITCH 2, n = 720). Available fasting SMBGs were used to determine the standard deviation (SD) of day-to-day fasting SMBG variability for each patient and the treatment combination. The association between day-to-day fasting SMBG variability and overall symptomatic, nocturnal symptomatic and severe hypoglycaemia was analysed for the pooled population using linear regression, with fasting SMBG variability included as a three-level factor defined by population tertiles. Finally, day-to-day fasting SMBG variability was compared between treatments.

resultsLinear regression showed that day-to-day fasting SMBG variability was significantly associated with overall symptomatic, nocturnal symptomatic and severe hypoglycaemia risk in T1D and T2D (P < 0.05). Day-to-day fasting SMBG variability was significantly associated (P < 0.01) with all categories of hypoglycaemia risk, with the exception of severe hypoglycaemia in T2D when analysed within tertiles. Degludec was associated with 4% lower day-to-day fasting SMBG variability than glargine U100 in T1D (P = 0.0082) and with 10% lower day-to-day fasting SMBG variability in T2D (P < 0.0001).

conclusionsHigher day-to-day fasting SMBG variability is associated with an increased risk of overall symptomatic, nocturnal symptomatic and severe hypoglycaemia. Degludec has significantly lower day-to-day fasting SMBG variability vs glargine U100.

Indexed as

AdolescentAdultBlood GlucoseBlood Glucose Self-MonitoringCircadian RhythmCross-Over StudiesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Double-Blind MethodFastingFemaleHumansHypoglycemiaInsulin GlargineInsulin, Long-ActingMaleBlood Glucoseinsulin degludecInsulin GlargineInsulin, Long-Actingbasal insulinhypoglycaemiainsulin therapytype 1 diabetestype 2 diabetes

Identifiers

PMID30362250
PMCPMC6587774
OpenAlexW2898326314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.